ATNM Actinium Pharmaceuticals, Inc. - 8-K

Item 3.01. Notice of Delisting or Failure to Satisfy a Continued
Listing Rule or Standard; Transfer of Listing.

On May 27, 2026, Actinium Pharmaceuticals, Inc.
(the “Company”) received a notice (the “Notice”) from NYSE American LLC (“NYSE American”) indicating
that the Company is not in compliance with the continued listing standards set forth in Section 1003(a)(ii) of the NYSE American Company
Guide (the “Company Guide”), which requires a listed company to maintain stockholders’ equity of $4.0 million or more
if it has reported losses from continuing operations and/or net losses in three of its four most recent fiscal years. As of March 31,
2026, the Company reported stockholders’ equity of approximately $2.3 million, and had net losses in its last five fiscal years
ended December 31, 2025.

In connection with its non-compliance with Sections
1003(a)(ii) and (iii) of the Company Guide, the Company must submit a plan by June 26, 2026, advising of actions it has taken or will
take to regain compliance with the continued listing standards by November 27, 2027 (“Plan Period Deadline”). If NYSE Regulation
determines to accept the plan, the Company will be notified in writing and will be subject to periodic reviews including quarterly monitoring
for compliance with the plan.

If the Company does not submit a plan or if the
plan is not accepted, delisting proceedings will commence. Furthermore, if the plan is accepted but the Company is not in compliance with
the continued listing standards by the Plan Period Deadline, or if the Company does not make progress consistent with the plan during
the plan period, NYSE American staff will initiate delisting proceedings as appropriate. The Company may appeal a staff delisting determination
in accordance with Section 1010 and Part 12 of the Company Guide.

The Notice has no immediate effect on the listing
or trading of the Company’s common stock, which will continue to trade on NYSE American under the symbol “ATNM,” subject
to the Company’s compliance with the other continued listing requirements of NYSE American, and will continue to trade with a “.BC”
indicator to denote that the Company is below compliance. The Company intends to submit a plan to NYSE American within the required timeframe.

There can be no assurance that the Company will
be able to regain compliance with the applicable continued listing standards, that the Company will submit a plan that is accepted by
NYSE American, that the Company will be able to comply with the terms of any accepted Plan, or that the Company will be able to maintain
the listing of its common stock on NYSE American.

Item 7.01. Regulation FD Disclosure.

On May 29, 2026, pursuant to Sections 402(g) and 1009(j) of the Company
Guide, the Company issued a press release announcing, among other things, its receipt of the Notice and providing an update on the development
program for its ATNM-400 product candidate. The full text of the press release is set forth below.

The information furnished pursuant to this Item 7.01 shall not be deemed
“filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or
otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing under the Securities
Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.

Description

99.1

Press Release dated May 29, 2026 (furnished pursuant to Item 7.01 of Form 8-K)

104

Cover Page Interactive Data File (embedded within the Inline XBRL document)

1